https://www.pharmaradar360.com/article/517c599588ec16b1PharmaRadar360en2026-05-10T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/3bfc2f7bc816ed37PharmaRadar360en2026-05-10T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/f84b79efbce3d96fPharmaRadar360en2026-05-10T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/666f245884f39b1dPharmaRadar360en2026-05-10T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/d8b1a11e8f33c372PharmaRadar360en2026-05-10T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/c21129657ed800b2PharmaRadar360en2026-05-10T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/e3ea3b98d6949131PharmaRadar360en2026-05-10T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/48c1e6eb3e80b179PharmaRadar360en2026-05-10T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/1dea332b605b04e2PharmaRadar360en2026-05-10T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/71a12e27485d4d7dPharmaRadar360en2026-05-10T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/d8850b62994bbd27PharmaRadar360en2026-05-10T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/7cd933d7ae238445PharmaRadar360en2026-05-10T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/92885555c7bd663bPharmaRadar360en2026-05-10T00:00:00.000Z6203https://www.pharmaradar360.com/article/77ba43ebf0002929PharmaRadar360en2026-05-10T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/05312d388cdba2eePharmaRadar360en2026-05-08T21:58:01.000ZJournal of Clinical Oncology: Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase 1/1b Trialhttps://www.pharmaradar360.com/article/aa4ccea105871c0cPharmaRadar360en2026-05-08T17:30:00.000Z当社に対する訴訟の提起に関するお知らせhttps://www.pharmaradar360.com/article/fc3c00e4ede711f4PharmaRadar360en2026-05-08T15:08:39.000ZStrategic Capital Supports Pivotal-Stage Executionhttps://www.pharmaradar360.com/article/50a3596be3cd3129PharmaRadar360en2026-05-08T14:49:03.000ZAspen Group Chief Operations Officer highlights Aspen’s role at the World Bank & IMF spring meetingshttps://www.pharmaradar360.com/article/d9ec32b6e8654f2aPharmaRadar360en2026-05-08T13:23:52.000ZZymeworks to Present at Respiratory Innovation Summit